Compare Abeona Therapeutics Inc (ABEO) vs GE Vernova Inc (GEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs GE Vernova Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while GE Vernova Inc trades at $1,089.35 (market cap $289.43B). The key difference: GE Vernova Inc is far larger — about 775.3× Abeona Therapeutics Inc's market cap, and GE Vernova Inc pays a 0.19% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GEV | |
|---|---|---|
Market Cap | $373.32M | $289.43B |
Sector | Health | Technology |
52-Week High | $7.23 | $1.17K |
52-Week Low | $4.17 | $530.00 |
Enterprise Value | $228.22M | $282.07B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GE Vernova (GEV) trades at $1,152.04, up 3.5% with strong bullish technical signals and robust fundamentals. The stock shows impressive profitability with 23.81% net margin and 83.23% ROE, though valuations appear elevated with P/E of 33.67. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q2 2026 estimates await. The company benefits from AI infrastructure demand, with gas turbines powering data centers driving growth.
Outlook remains positive given AI-driven power infrastructure demand and raised 2026 guidance, but premium valuation and execution risks warrant caution. Analyst consensus strongly favors buying with $1,220 price target, representing 6% upside. Key risks include valuation sensitivity and competitive pressures in energy transition markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
